Continuous glucose monitoring to track metabolic changes in youths with cystic fibrosis before and after initiation of elexacaftor/tezacaftor/ivacaftor therapy
Authors' conclusion
ETI is associated with improvement of CGM glucose in children and adolescents with CF. TA140 before ETI initiation may impact the trajectory of clinically relevant outcomes.
Study context
- Population
- Youths aged 2–18 years with cystic fibrosis from the French MODUL-CF real world study, with ≥24 hours of CGM data before elexacaftor/tezacaftor/ivacaftor (ETI) initiation and a 2nd CGM 12±3 months after ETI start98 enrolled
- Participants
- 13 / 55 / 32
- Exposure
- CGM metrics before vs after elexacaftor/tezacaftor/ivacaftor initiation
- Preschooln = 13
- School agen = 55
- Adolescentsn = 32
- Outcome
- CGM-derived glucose metrics before vs after ETI
- Follow-up
- 12±3 months after ETI start
Methodological detailsreal world, before-after comparison, stratified by age at ETI initiation
- Real world
- Before-after comparison
- Stratified by age at ETI initiation
Main finding
As reported in the abstract
Time in tight glucose range (TITR)
- TITR at baseline (whole cohort)
- 89.8%(84.1, 93.4)
- Whole cohort spending >10% of time >140mg/dL (TA140) at baseline
- 34%
- TITR increase after ETI
- ∼2%(+1.8[−1.8, +6.0]%) (p=0.004)
- Reduction of mild hyperglycemia (>140mg/dL) after ETI
- 0.4%
- CV before vs after ETI
- 21.5%(19.0, 24.7) vs 19.6%(17.0, 22.6), p<0.001
Observational data: associations, not effects.
Further findings
Weight gain and lung function by baseline TA140
- TA140≤10% at baseline had greater weight gain and lung function improvement vs TA140>10%
Original publication
Continuous glucose monitoring to track metabolic changes in youths with cystic fibrosis before and after initiation of elexacaftor/tezacaftor/ivacaftor therapy. J Clin Endocrinol Metab. Published 31 August 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →